GET DAILY SIGNALSSchrödinger (SDGR) Advances +13% Over 30 Days on AI Catalysts and Analyst Upgrades
Key Takeaways
- SDGR shares rose roughly 13% over the trailing 30 days, moving from about $26.39 to $29.82, despite a sharp mid-October pullback and subsequent recovery.
- The recent move builds on a broader advance, with shares up approximately 64% over the last quarter after a strong September rally.
- October analyst price-target increases, including BMO Capital raising its target to $30 and KeyBanc lifting its to $32, helped support the rebound.
- Company-specific catalysts include the Bunsen agentic-AI launch, a strategic software agreement with Bristol Myers Squibb, and the September formation of Tectora Therapeutics.
- Elevated short interest of roughly 15% of the float added to volatility during the period.
- Third-quarter 2026 results were reported on November 4, with attention focused on software annual contract value, the hosted-software transition, and Bunsen adoption.
Schrödinger's Platform and Market Position
Schrödinger, Inc. develops a physics-based computational platform that combines molecular simulation, machine learning, and artificial intelligence to speed up drug discovery and materials design. Its software tools, including FEP+, WaterMap, and LiveDesign, are licensed by biopharmaceutical companies, industrial firms, and academic institutions around the world. The company also runs a drug discovery segment that advances proprietary and collaborative programs, offering potential upside from milestones, royalties, and equity stakes in co-founded entities.
Investors track SDGR because it operates at the intersection of high-performance computing, AI-driven drug discovery, and an emerging pipeline of partnered and proprietary therapeutics. Recurring software revenue provides some stability, while collaborative programs create event-driven upside tied to clinical and business development milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: 30 Days Versus the Quarter
Over the trailing 30 days, SDGR shares moved from a closing price of $26.39 to approximately $29.82, a gain of about 13%. The path was far from straight: after touching an intraday high near $33 in early October, the stock pulled back to roughly $22.60 in mid-October before mounting a strong recovery into early November.
The last-quarter trend is even more pronounced. From a level near $18 in early August, shares have risen roughly 64%, reflecting a sustained re-rating driven by AI-related enthusiasm, positive earnings news, and a series of strategic announcements. This quarterly advance follows a multi-year period in which the stock traded well below its 2021 all-time highs.
What Drove the 30-Day Move
Several factors shaped SDGR trading over the past month. On the analyst front, BMO Capital raised its price target to $30 from $24 while maintaining an Outperform rating in mid-October, and KeyBanc lifted its target to $32 from $20 with an Overweight rating, citing elevated expectations heading into third-quarter results. UBS separately adjusted its target to $21 from $19 while maintaining a Neutral stance.
The stock’s early-to-mid October weakness occurred against a backdrop of profit-taking following an outsized September run, compounded by high short interest of roughly 15% of the float. The subsequent rebound gathered pace as the company announced it would report third-quarter 2026 results on November 4 and as management prepared to present at the UBS Global Healthcare Conference.
Broader enthusiasm for AI-enabled drug discovery platforms also remained a tailwind, with investors focused on the adoption of Bunsen, Schrödinger’s agentic AI co-scientist, and on the company’s transition toward hosted software contracts.
Drivers Behind the Quarterly Advance
The quarterly advance was powered by a series of company-specific developments. In August, Schrödinger reported second-quarter 2026 results that exceeded expectations, posting total revenue of $58.9 million and a return to quarterly net income, aided by milestone and equity gains tied to Eli Lilly’s (LLY) acquisition of Ajax Therapeutics. Management also highlighted 27% year-over-year growth in software ACV and the launch of Bunsen, followed by a strategic software agreement with Bristol Myers Squibb (BMY) to deploy the platform.
In September, Schrödinger co-founded Tectora Therapeutics with New Enterprise Associates and RA Capital, contributing two early-stage small-molecule programs in exchange for an equity stake plus potential milestones and royalties. These catalysts established a narrative of recurring software growth, AI platform adoption, and portfolio monetization that has underpinned the stock’s multi-month re-rating.
Key Metrics to Watch Going Forward
Looking ahead, investors are likely to monitor several key drivers. Software annual contract value and the pace of the hosted-software transition will remain central to assessing underlying demand. Adoption of Bunsen across pharmaceutical partners, including the Bristol Myers Squibb deployment, will be watched as a signal of the platform’s commercial traction.
Additional catalysts include progress across Schrödinger’s collaborative and proprietary pipeline, potential milestones and royalties from co-founded companies such as Tectora Therapeutics and Nimbus, and further analyst estimate revisions. Macroeconomic factors, including interest-rate dynamics, also remain relevant. Investors should weigh these factors against the stock’s elevated volatility and notable short interest.
Using Tickeron AI Trading Bots for Strategy Testing
In my own research process, I frequently turn to Tickeron’s AI Trading Bots to evaluate systematic approaches alongside traditional analysis. The platform offers hundreds of automated strategies that monitor thousands of tickers, allowing users to identify those that align with current market conditions and personal risk parameters. This helps provide an additional layer of context when reviewing names like SDGR that combine software growth with event-driven upside. Explore the full selection at AI Trading Bots to see how different bots have performed across varying timeframes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SDGR's Stochastic Oscillator entering overbought zone
The Stochastic Oscillator for SDGR moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SDGR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 24 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SDGR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SDGR as a result. In 70 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for SDGR just turned positive on October 28, 2026. Looking at past instances where SDGR's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
SDGR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SDGR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 215 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 137 of 187 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.781) is normal, around the industry mean (4.477). SDGR has a moderately low P/E Ratio (-40.849) as compared to the industry average of (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of chemical simulation software solutions to pharmaceutical industry.
Industry ServicestotheHealthIndustry
Advertisement